Alemtuzumab (Campath)

An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.

Also Known As:

Campath; Campath 1H; Campath 1G; Campath 1M; Campath-1-G; Campath-1G; Campath-1H; Campath-1M; Lemtrada; MabCambath; Monoclonal Antibody Campath-1H; Antibody Campath-1H, Monoclonal; Campath 1 G; Campath-1H, Monoclonal Antibody; Campath1G; Campath1H; Monoclonal Antibody Campath 1H

Networked: 1758 relevant articles (234 outcomes, 281 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Coles, Alasdair J: 33 articles (01/2022 - 01/2006)
2.	Wiendl, Heinz: 25 articles (01/2022 - 01/2012)
3.	Meuth, Sven G: 22 articles (03/2022 - 01/2012)
4.	Margolin, David H: 21 articles (01/2021 - 10/2008)
5.	Mackinnon, Stephen: 20 articles (05/2017 - 02/2002)
6.	Coles, Alasdair: 18 articles (03/2022 - 06/2004)
7.	Ruck, Tobias: 18 articles (03/2022 - 03/2015)
8.	Giovannoni, Gavin: 18 articles (01/2022 - 03/2012)
9.	Ziemssen, Tjalf: 18 articles (01/2022 - 01/2015)
10.	Jones, Joanne L: 17 articles (01/2022 - 01/2008)

Related Diseases

1.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 07/01/2018 - "We suggest that the long existing safety guidelines for alemtuzumab infusion in B-cell chronic lymphocytic leukemia might be also beneficial in the MS setting. " 03/01/2012 - "Alemtuzumab has been shown to be effective in poor-prognosis chronic lymphocytic leukemia (CLL); treatment, however, has been associated with significant toxicity. " 06/01/2007 - "With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (cll)?What toxicities are associated with the use of alemtuzumab?Which" 06/01/2009 - "Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics Alemtuzumab is effective in B-cell chronic lymphocytic leukemia (CLL) with 17p deletion, which responds poorly to chemotherapeutic agents. " 01/15/2005 - "The anti-CD52 antibody alemtuzumab is effective in the treatment of patients with chronic lymphocytic leukemia (CLL). "
2.	Multiple Sclerosis 03/01/2022 - "Alemtuzumab is a highly effective treatment for multiple sclerosis (MS) and the treatment strategy of two cycles 12 months apart has a lot of appeal to patients. " 01/01/2018 - "Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. " 01/01/2015 - "In clinical trials, alemtuzumab has shown impressive efficacy with regard to clinical and radiological outcomes in relapsing multiple sclerosis, along with sustained long-term beneficial effects, and it is attractive for its once-yearly administration. " 01/01/2021 - "aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis." 05/01/2023 - "Alemtuzumab is effective in reducing relapse rate and disability, but limited data exist on its effect on cognitive function in relapsing multiple sclerosis (RMS). "
3.	Relapsing-Remitting Multiple Sclerosis 07/01/2023 - "Alemtuzumab is a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), but in recent years safety-related concerns had emerged due to description of novel serious side effects not registered in CARE-MS I and CARE-MS II phase 3 studies, nor in TOPAZ extension study. " 01/01/2021 - "Alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis. " 10/01/2020 - "Alemtuzumab is highly effective in relapsing remitting multiple sclerosis (RRMS), but autoimmune adverse events are of concern. " 09/01/2020 - "Alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis (MS). " 01/01/2019 - "The lymphocyte-depleting antibody alemtuzumab is a highly effective treatment of relapsing-remitting multiple sclerosis (RRMS); however 50% of patients develop novel autoimmunity post-treatment. "
4.	Neoplasms (Cancer) 08/01/1993 - "The humanized antibody CAMPATH-1H has been shown in pilot studies to be beneficial in the treatment of lymphoid malignancy and other lymphoproliferative diseases. " 12/01/2004 - "Alemtuzumab greatly reduced tumor mass in blood and bone marrow, B-symptoms resolved, and organomegaly improved. " 12/19/1995 - "Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H." 01/01/2017 - "Studying the effects on HIV persistence following immune recovery in HIV-infected individuals who require alemtuzumab for malignancy or in animal studies may provide further insights into novel cure strategies." 03/01/2015 - "The adverse effects of alemtuzumab reported in these trials had already been observed in cancer patients. "
5.	Infections 02/01/2006 - "Alemtuzumab (Campath-1H)-based conditioning regimens are effective in preventing GVHD, but are associated with very high rates of cytomegalovirus (CMV) infection, a major limitation to their use. " 08/01/2005 - "Low-dose alemtuzumab induced significant responses in these patients (16% complete remission, 25% partial remission), with mild hematologic and extrahematologic side effects and a low rate of infections, even in the presence of long-lasting severe immunosuppression." 11/01/2007 - "We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection." 04/01/2003 - "Thus elimination of late mortalities related to chronic GVHD and a rapid immune reconstitution, limiting either infection or relapse related deaths, contributed to an improved outcome following T-cell depletion with Campath-1H "in the bag"." 01/01/2023 - "In conclusion, alemtuzumab is an effective treatment for severe kidney transplant rejection, but causes long-lasting lymphocyte depletion and is associated with frequent infections and worse patient survival outcomes."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Rituximab (Mabthera)
3.	fludarabine
4.	Alemtuzumab (Campath)
5.	Interferon beta-1a
6.	Natalizumab (Tysabri)
7.	Interferons
8.	Cyclophosphamide (Cytoxan)
9.	Fingolimod Hydrochloride (FTY720)
10.	Cladribine

Related Therapies and Procedures

1.	Therapeutics
2.	Stem Cell Transplantation
3.	Drug Therapy (Chemotherapy)
4.	Transplantation
5.	Hematopoietic Stem Cell Transplantation